Information Journal Paper
APA:
Copy. (2017). Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity. CELL DEATH DISEASE, 8(4), 0-0. SID. https://sid.ir/paper/735851/en
Vancouver:
Copy. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity. CELL DEATH DISEASE[Internet]. 2017;8(4):0-0. Available from: https://sid.ir/paper/735851/en
IEEE:
Copy, “Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity,” CELL DEATH DISEASE, vol. 8, no. 4, pp. 0–0, 2017, [Online]. Available: https://sid.ir/paper/735851/en